APPIA Mission Statement

The Anatomic Pathology Patient Interest Association (APPIA) is a not for profit organization focused on advancing patient safety, quality, standards, and accessibility of care in anatomic pathology.

About APPIA

The Anatomical Pathology Patient Interest Association was founded and incorporated in 2016. APPIA is a non-profit, membership organization that exists to promote educational and professional interests and to develop best practices while providing a vehicle for advocacy for those working in the field of anatomical pathology. This benefits the public by increasing patient safety, quality and standards of care, accessibility of care, and social responsibility in anatomic pathology. We are currently striving to achieve these goals today.

Board of Directors

President

Erico von Bueren (Sakura Finetek USA, Inc.) Erico von Bueren is the Director of Marketing for Sakura Finetek USA, Inc. After his study and Doctorate in Medicine (Milano, Essen, Bochum, Frankfurt, Universities in Italy and Germany) and Masters in Operations Research (Aachen, Germany), Mr. von Bueren started his career in the pharmaceutical industry in medical, product and marketing management in several therapeutic areas (Ferring Pharmaceuticals and Schwarz Pharma/UCB). After 10 years, he switched to the in-vitro diagnostic industry concentrating on the fields of flow cytometry and anatomic pathology (Dako/Agilent, Denmark and U.S.A., and Thermo Fisher Scientific, U.S.A.). Now at Sakura Finetek USA, his focus in commercial and global product and market development resides in automating and standardizing anatomic pathology through continuous innovation.

President-Elect

Shalini Singh (Roche Diagnostics Solutions) Dr. Shalini Singh is a pathologist and is Head of Pathology at Roche Tissue Diagnostics in Tucson, AZ. She has been with Roche for 13 years. Her primary interests include Digital pathology, personalized healthcare, molecular pathology, translational oncology, and immunotherapy. She is licensed physician with expertise in molecular and genetic pathology and companion diagnostics. She is a Fellow of the College of American Pathologists and collaborates with CAP foundation Educational Grant for residents’ rotation at Roche Tissue Diagnostics. She is an expert in strategic partnerships between Pharma and Diagnostics collaboration.

Immediate Past President

Beth Sheppard

Ms. Sheppard has worked in both private and academic management of Anatomic Pathology laboratories and industry for the past 30 years. Her passion to influence the pathology profession includes committee involvement at College of American Pathologist (CAP), ASCP, ISO, CLSI and is past President of the National Society of Histotechnology (NSH).

Treasurer

Doug Felten (Agilent Technologies, Inc.) Mr. Felten is the Director, Segment Marketing for the Americas Diagnostics and Genomics Group, for Agilent. He possesses over thirty (30) years of experience in laboratory diagnostics across the spectrum of Chemistry/ Immunochemistry, Laboratory Automation, Molecular, Pathology and Genomics disciplines. Mr. Felten’s career has spanned Abbott Diagnostics, Roche Diagnostics/ Centralized Diagnostics and Agilent to include individual contributor and leadership roles of increasing responsibility in both Sales and Marketing.

Benefactor Director

George Kennedy (Sakura Finetek USA, Inc.) Mr. Kennedy is the Senior Vice President of Sales and Marketing for Sakura Finetek USA, Inc.  He possesses over 40 years of experience in laboratory diagnostics with a focus on commercialization of cancer diagnostics including executive leadership positions as Leica Biosystems, Vysis Incorporated (now Abbott Diagnostics) and Dianon Systems (now LabCorp).  Mr. Kennedy started his career as a Medical Technologist and transitioned into industry with positions of increasing responsibility in sales, sales management, marketing management and executive positions.

Benefactor Director

Olga Kolman (Leica Biosystems) Dr. Kolman is a pathologist with experience in academic practice, strategy consulting, biopharma and diagnostic industries. Dr. Kolman is currently the Medical Director and Pathologist at Leica Biosystems. Prior to this, she served as Sr. Director of Corporate Strategy and Disease Area Innovation at Biogen and Head of New Product Planning at Sigilon Therapeutics. Dr. Kolman’s career spanned roles of increasing responsibility within the R&D organization at Shire and strategy consulting for IVD and biopharma industry at Health Advances. Dr. Kolman completed residency and anatomic pathology fellowship training at Massachusetts General Hospital.

Benefactor Director

Angie Cahill (Roche Diagnostics Solutions) Ms. Cahill is a Senior International Product Manager in the Oncology Core Assays Lifecycle for Roche and is a certified histotech, HT (ASCP). She’s spent over 25 years in laboratory diagnostics across Anatomic Pathology, Coagulation, Chemistry/Immunochemistry and Laboratory Automation disciplines. Ms. Cahill’s career has spanned OhioHealth, Sigma Diagnostics, Beckman Coulter and Roche Diagnostics to include individual contributor and leadership roles of increasing responsibility in Sales, Service Management, and Marketing. Her previous work with APPIA includes membership to the Pre-analytics Subcommittee which produced best-practice educational material for all stakeholders involved in the specimen collection and transport process.

Benefactor Director

Bryce Portier (Agilent Technologies, Inc.) Dr. Portier is a pathologist with experience in both academic practice and the diagnostic industry. Dr. Portier is currently the Enterprise Medical Director and Head of Medical Affairs for Agilent. Previously, he served as Sr. Director of Medical Affairs for Companion Diagnostics (CDx) at Roche/Ventana based out of Tucson, Arizona. Prior to that, Dr. Portier was a practicing pathologist at one of the largest hospital systems in Houston, Texas. He held a dual academic appointment as both Director of molecular diagnostics laboratory and as a principal investigator investigating utility of aptamers as diagnostics in breast cancer. Dr. Portier is a professional licensed physician with expertise in molecular and genetic pathology as well as an expert in strategic medical launch partnerships between diagnostic / pharma.

Benefactor Director

David Ferber (Leica Biosystems) Dr. Ferber is a pathologist and Senior Medical and Scientific Affairs liaison at Leica Biosystems. He has greater than 20 years of experience in anatomic and clinical practice with special interest/expertise in genitourinary pathology. He has held many roles during his clinical career including director of the autopsy service, supervisor of pathology assistants, transitional resident faculty, pathology representative on Cancer Committee, and member of virtual tumor board project. He is a graduate of University of Wisconsin School of Medicine and Public Health and completed residency at Medical College of Wisconsin. He is a fellow of the College of American Pathologists and member of the Digital Pathology Society. He is a licensed physician particularly interested in digital pathology and innovation eager to take on the challenges of his role as medical science liaison.